Abstract
Aim:
To construct pEGFP-N3 recombinant vectors carrying adrenomedullin (AM) or fragments of the AM gene, and to express AM or fragments of AM from the pEGFP-N3 recombinant vectors (pEGFP-N3-AM1-2 and pEGFP-N3-AM1-3) and study their biological properties on cultured rat renal mesangial cells (RMC).
Methods:
Total RNA of rat kidney was obtained using TriZol reagent. The cDNA was synthesized by reverse transcriptase using oligo-deoxythymidine as primer. The fragments of AM gene were then amplified by polymerase chain reaction (PCR) with specific upstream and downstream oligonucleotides. The PCR products were digested with EcoRI and BamHI and subcloned into the plasmid pEGFP-N3. Facilitated by cationic liposomes, RMC were transfected with pEGFP-N3-AM1-2 or pEGFP-N3-AM1-3. After 24 h, green fluorescent protein (GFP) fluorescent images were examined with a fluorescence microscope. After 48 h, the proliferation of RMC was detected using the MTT assay, and the mRNA expression of transforming growth factor-β1 (TGF-β1) was measured by semiquantitative PCR.
Results:
DNA sequence reports verified that pEGFP-N3-AM1-2, which carried the full length AM gene translation fragment (preproadrenomedullin preproAM1–185), and pEGFP-N3-AM1-3, which carried the translation fragment of preproAM [without adrenotensin (ADT, preproAM150-185)], were constructed successfully. After 24 h, green fluorescence was observed in RMC into which either pEGFP-N3-AM1-2 or pEGFP-N3-AM1-3 was transfected, while in the control cells no fluorescence was observed. Either pEGFP-N3-AM1-2 or pEGFP-N3-AM1-3 delivery inhibited the proliferation of RMC (P < 0.01) and decreased the mRNA transcription level of TGF-β1 in RMC (P < 0.05). However, no significant difference was observed between the effects of pEGFP-N3-AM1-2 and pEGFP-N3-AM1-3.
Conclusion:
pEGFP-N3-AM1-2 and pEGFP-N3-AM1-3 were constructed successfully and were functionally expressed in RMC. Expressing the fragment of AM without ADT has similar inhibitory biological effects on RMS proliferation and TGF-β1 transcription with full length preproAM.
Similar content being viewed by others
Article PDF
References
Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. AM: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192: 553–60.
Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T . Distribution and characterization of immunoreactive AM in human tissue and plasma. FEBS Lett 1994; 338: 6–10.
Beltowski J, Jamroz A . Adrenomedullin–what do we know 10 years since its discovery? Pol J Pharmacol 2004; 56: 5–27.
Bunton DC, Petrie MC, Hillier C, Johnston F, McMurray JJ . The clinical relevance of adrenomedullin: a promising profile? Pharmacol Ther 2004; 103: 179–201.
Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K, et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994; 94: 2158–61.
Kato J, Kobayashi K, Etoh T, Tanaka M, Kitamura K, Imamura T, et al. Plasma adrenomedullin concentration in patients with heart failure. J Clin Endocrinol Metab 1996; 81: 180–3.
Mori Y, Nishikimi T, Kobayashi N, Ono H, Kangawa K, Matsuoka H . Long-term adrenomedullin infusion improves survival in malignant hypertensive rats. Hypertension 2002; 40: 107–13.
Chao J, Chao L . The role of adrenomedullin in cardiovascular and renal function. Drug News Perspect 2002; 15: 511–8.
Sakata J, Shimokubo T, Kitamura K, Nakamura S, Kangawa K, Matsuo H, et al. Molecular cloning and biological activities of rat adrenomedullin, a hypotensive peptide. Biochem Biophys Res Commun 1993; 195: 921–7.
Hinson JP, Kapas S, Smith DM . Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000; 21: 138–67.
Gumusel B, Chang JK, Hyman A, Lippton H . Adrenotensin: an ADM gene product with the opposite effects of ADM. Life Sci 1995; 57: PL87–90.
Gumusel B, Chang JK, Hao Q, Hyman A, Lippton H . Adrenotensin: an adrenomedullin gene product contracts pulmonary blood vessels. Peptides 1996; 17: 461–5.
Nakamura R, Kato J, Kitamura K, Imamura T, Eto T . Potential of adrenomedullin as a therapeutic tool for left ventricular remodeling after myocardial infarction. Nippon Rinsho 2004; 62: 302–6.
Savoia C, Schiffrin EL . Significance of recently identified peptides in hypertension: endothelin, natriuretic peptides, adrenomedullin, leptin. Med Clin North Am 2004; 88: 39–62.
Meeran K, O'Shea D, Upton PD, Small CJ, Ghatei MA, Byfield PH, et al. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab 1997; 82: 95–100.
Chao J, Jin L, Lin KF, Chao L . Adrenomedullin gene delivery reduces blood pressure in spontaneously hypertensive rats. [ published erratum appears in Hypertens Res 2001; 24: 611]. Hypertens Res 1997; 20: 269–77.
Dobrzynski E, Montanari D, Agata J, Zhu J, Chao J, Chao L . Adrenomedullin improves cardiac function and prevents renal damage in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2002; 283: E1291–8.
Wang C, Dobrzynski E, Chao J, Chao L . Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am J Physiol Renal Physiol 2001; 280: F964–71.
Zhang JJ, Yoshida H, Chao L, Chao J . Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive dahl salt-sensitive rats. Hum Gene Ther 2000; 11: 1817–27.
Dobrzynski E, Wang C, Chao J, Chao L . Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 2000; 36: 995–1001.
Pachori AS, Huentelman MJ, Francis SC, Gelband CH, Katovich MJ, Raizada MK . The future of hypertension therapy: sense, antisense, or nonsense? Hypertension 2001; 37: 357–64.
Lin KF, Chao L, Chao J . Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension 1997; 30: 307–13.
Kurogi Y . Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. Med Res Rev 2003; 23: 15–31.
Parameswaran N, Nambi P, Brooks DP, Spielman WS . Regulation of glomerular mesangial cell proliferation in culture by adrenomedullin. Eur J Pharmacol 1999; 372: 85–95.
Parameswaran N, Nowak W, Hall CS, Sparks HV, Spielman WS . Cellular and molecular actions of adrenomedullin in glomerular mesangial cells. Peptides 2001; 22: 1919–24.
Chini EN, Choi E, Grande JP, Burnett JC, Dousa TP . Adrenomedullin suppresses mitogenesis in rat mesangial cells via cAMP pathway. Biochem Biophys Res Commun 1995; 215: 868–73.
Sporn MB, Roberts AB . Transforming growth factor-beta: recent progress and new challenges. J Cell Biol 1992; 119: 1017–21.
Sharma K, Jin Y, Guo J, Ziyadeh FN . Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996; 45: 522–30.
Qi YF, Bu DF, Niu da D, Shi YR, Wang SH, Pang YZ, et al. Effects of different peptide fragments derived from proadrenomedullin on gene expression of adrenomedullin gene. Peptides 2002; 23: 1141–7.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the National Natural Science Foundation of China (No 30470627) and the Funds for Graduate Education sponsored by the Ministry of Education (No 20010246012).
Rights and permissions
About this article
Cite this article
Chen, Sw., Wang, Xf., Shao, Y. et al. Similar effects on rat renal mesangial cells by expressing different fragments of adrenomedullin gene in vitro. Acta Pharmacol Sin 26, 845–850 (2005). https://doi.org/10.1111/j.1745-7254.2005.00138.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00138.x